Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
Rhea-AI Summary
Bionoid Pharma (OTC PINK:BINP) has announced the completion of its financial audits for fiscal years 2022 and 2023 by PCAOB-registered firm Olayinka Oyebola & Co. This development represents a key milestone in the company's commitment to financial transparency and regulatory compliance.
The audits were conducted according to Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy of Bionoid's financial reporting. The firm is also on schedule to complete the company's 2024 financial statements.
CEO Wayne Cockburn emphasized that this achievement aligns with Bionoid's expansion strategy, which focuses on strategic acquisitions and AI-driven growth initiatives. The company is particularly targeting revenue-generating e-commerce acquisitions and continues to integrate its AI Maverick platform for sustainable growth.
Positive
- Successful completion of 2022 and 2023 financial audits by PCAOB-registered firm
- On track for timely completion of 2024 financial statements
- Strategic focus on revenue-generating e-commerce acquisitions
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, BINP declined 2.00%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by Olayinka Oyebola & Co., a PCAOB-registered firm. This milestone marks a significant step in Bionoid's commitment to financial transparency and regulatory compliance as the company continues executing its long-term growth strategy.
Olayinka Oyebola & Co. has worked diligently to complete the audits in accordance with Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy and integrity of Bionoid's financial reporting. The firm remains on track to finalize the company's 2024 financial statements as scheduled, further strengthening Bionoid's financial standing.
"The completion of our 2022 and 2023 audits is a critical achievement for Bionoid and underscores our dedication to financial accountability," said Wayne Cockburn, CEO of Bionoid Pharma, Inc. "As we continue our expansion through strategic acquisitions and AI-driven growth initiatives, maintaining strong financial governance remains a top priority. We appreciate the expertise and professionalism of Olayinka Oyebola & Co. and look forward to the timely completion of our 2024 financials."
Bionoid remains focused on scaling its operations through revenue-generating e-commerce acquisitions and the integration of its AI Maverick platform, positioning the company for sustainable growth and enhanced investor confidence.
About Bionoid Pharma, Inc.
Bionoid Pharma, Inc. is a forward-thinking health and wellness company dedicated to expanding revenue streams and brand presence through strategic acquisitions and advanced AI technology. Its proprietary AI Maverick platform enhances customer engagement and operational efficiency, supporting the company's mission to deliver innovative, AI-driven solutions for long-term growth.
Stay connected:
Website: BionoidPhama.com
OTC Markets: BINP
For further information, contact:
Wayne Cockburn, CEO
Phone: (905) 505-0770
Email: bionoidpharma@gmail.com
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
FAQ
What is the significance of BINP completing its 2022 and 2023 financial audits?
Who conducted Bionoid Pharma's (BINP) 2022-2023 financial audits?
What are BINP's current growth strategies according to the announcement?
When will BINP's 2024 financial audit be completed?
